PDCD1 and neoplasm: Combination therapies are being explored, with fucoidan showing synergism with immune checkpoint inhibitors (e.g., anti-PD-1) by reversing T cell exhaustion, as demonstrated in a mouse melanoma model where the combination reduced tumor volume by 70% [175].